Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Characterisation of HS-5 bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia
EF 2022-23
Résumé
Leukemia is the most common cancer type in young children under 14. Acute myeloid leukemia accounts for ~20% of these cases and is a deadly disease with an overall survival rate of only ~60%. Through a small molecule screen, the Wilhelm lab has identified 130 compounds with anti-leukemic properties against patient samples, cell lines, and our pediatric leukemia model samples. Interestingly, ~1/3 of these compounds lose their effectiveness against leukemic cell lines when cultured with the HS-5 bone marrow (BM) stromal cell line. Published literature has shown that HS-5 cells can protect leukemic cells against standard chemotherapy and that this effect is enhanced when the cells are in contact. This mirrors animal studies highlighting the importance of alterations in the BM microenvironment of leukemic patients, however the mechanisms of this BM chemoprotection remain poorly defined. The goal of this project is to define the mechanisms of chemoresistance of acute myeloid leukemia in direct contact with the HS-5 cell line. Firstly, I will re-screen 70 of the compounds using the HS-5 co-culture model to select 5-8 compounds where resistance is clearly observed for further study. I will then use RNA sequencing and a targeted CRISPR screen of surface proteins to investigate those involved in chemoresistance. The former will be used to identify altered gene expression levels of the AML cell lines and HS-5 with or without drug exposure and the latter uses CRISPR technology to knockout a single protein in a single cell. These cells will then be isolated and put in co-culture to determine whether the deleted protein is involved in chemoresistance. In conclusion, this work will help define chemoresistance mechanisms in acute myeloid leukemia, which could be targets for therapy.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
485907
Name
Lussier Tyler E
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterisation of HS-5 bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Acute Myeloid Leukemia; Cell-Cell Interactions; Chemoresistance; Coculture; Drug Screen; Flow Cytometry; Leukemia Microenvironment; Pediatric Leukemias; Rna Sequencing; Targeted Crispr Screen
Abstract
Leukemia is the most common cancer type in young children under 14. Acute myeloid leukemia accounts for ~20% of these cases and is a deadly disease with an overall survival rate of only ~60%. Through a small molecule screen, the Wilhelm lab has identified 130 compounds with anti-leukemic properties against patient samples, cell lines, and our pediatric leukemia model samples. Interestingly, ~1/3 of these compounds lose their effectiveness against leukemic cell lines when cultured with the HS-5 bone marrow (BM) stromal cell line. Published literature has shown that HS-5 cells can protect leukemic cells against standard chemotherapy and that this effect is enhanced when the cells are in contact. This mirrors animal studies highlighting the importance of alterations in the BM microenvironment of leukemic patients, however the mechanisms of this BM chemoprotection remain poorly defined. The goal of this project is to define the mechanisms of chemoresistance of acute myeloid leukemia in direct contact with the HS-5 cell line. Firstly, I will re-screen 70 of the compounds using the HS-5 co-culture model to select 5-8 compounds where resistance is clearly observed for further study. I will then use RNA sequencing and a targeted CRISPR screen of surface proteins to investigate those involved in chemoresistance. The former will be used to identify altered gene expression levels of the AML cell lines and HS-5 with or without drug exposure and the latter uses CRISPR technology to knockout a single protein in a single cell. These cells will then be isolated and put in co-culture to determine whether the deleted protein is involved in chemoresistance. In conclusion, this work will help define chemoresistance mechanisms in acute myeloid leukemia, which could be targets for therapy.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lussier, Tyler E
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~